Strengthening the Foundation as a Global Company
First written in FY2016. 17 of 22 entries say "Advanced", first in FY2017-Q2. Latest entry: FY2026.
Zeria Pharmaceutical moved to the "Worse" side of this theme in 2018, 2 years before the typical company in this theme (2020).
The whole theme swung hardest in 2023: 2 of 20 companies on the "Worse" side.
10 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「Regarding the first key priority, global expansion, we will further expand our operations in Europe and Asia. In Europe, we will accelerate licensing activities to introduce products that will become growth drivers following DIFICLIR」
In addition to expanding operations in Europe and Asia, the 12th Medium-Term Management Plan set out specific measures to accelerate the introduction through licensing of growth products to follow DIFICLIR. - FY2026-H1WorsenedAnnual report
「The overseas sales ratio for the current interim consolidated period was 54.5% (56.9% in the previous consolidated fiscal year). Sales for the current interim consolidated period declined from the previous interim consolidated period because of, among other factors, a malfunction in production equipment at the plant contracted to manufacture ASACOL, which resulted in insufficient product supplies for a certain period. The production equipment has since been restored, and the product supply system has already returned to normal.」
The overseas sales ratio declined from 56.9% to 54.5%. In addition, a malfunction in equipment at the contract manufacturing plant for ASACOL temporarily caused insufficient product supplies and contributed to the decline in overseas sales, but the equipment was restored and the supply system returned to normal. - FY2025AdvancedAnnual report
「In our global operations, in addition to continuously expanding our European business centered on DIFICLIR and ASACOL, we will focus on expanding our business in the rapidly growing Asian region. The overseas sales ratio for the current consolidated fiscal year was 56.9% (51.5% in the previous fiscal year).」
The Group continued its European operations centered on DIFICLIR and ASACOL and its Asian operations, while the overseas sales ratio rose from 51.5% in the previous fiscal year to 56.9%. - FY2025-H1AdvancedAnnual report
「The overseas sales ratio for the current interim consolidated period was 55.7% (51.5% in the previous consolidated fiscal year). Agreement concerning the exclusive development and sale of the functional dyspepsia treatment Acofide in Europe, the United States and Canada」
The overseas sales ratio rose from 51.5% to 55.7%. In addition, the Group entered into an exclusive development and sale agreement for Acofide in Europe, the United States and Canada dated 19 June 2024, expanding the target regions for its global operations. - FY2024AdvancedAnnual report
「The overseas sales ratio for the current consolidated fiscal year was 51.5% (47.4% in the previous fiscal year).」
The overseas sales ratio rose from 47.4% in the previous fiscal year to 51.5%, advancing the expansion of the global business foundation. - FY2024-Q1AdvancedAnnual report
「The overseas sales ratio for the first quarter of the current consolidated cumulative period was 50.4% (47.4% in the previous consolidated fiscal year).」
The overseas sales ratio rose from 47.4% in the previous consolidated fiscal year to 50.4%, further numerically demonstrating the expansion of the global business foundation. - FY2023AdvancedAnnual report
「In our global operations, we will continue to focus more closely on expanding our business in Europe and Asia, centered on our 3 overseas subsidiaries. In Europe, we will seek the continued development and expansion of the European business by establishing a new European Business Division and strengthening cooperation with our European subsidiaries.」
The Group continued its Europe and Asia expansion centered on its overseas subsidiaries, and proceeded to strengthen cooperation with its European subsidiaries by establishing a new European Business Division. - FY2023-Q3AdvancedAnnual report
「The overseas sales ratio for the third quarter of the current consolidated cumulative period was 46.4% (41.4% in the previous consolidated fiscal year).」
Although the overseas sales ratio declined from 47.4% in the second quarter, it was 46.4%, above the 41.4% recorded in the previous consolidated fiscal year, continuing to demonstrate expansion of the global business foundation. - FY2023-Q2AdvancedAnnual report
「The overseas sales ratio for the second quarter of the current consolidated cumulative period was 47.4% (41.4% in the previous consolidated fiscal year).」
The overseas sales ratio rose from 41.4% in the previous consolidated fiscal year to 47.4%, numerically demonstrating the expansion of the global business foundation. - FY2023-Q1AdvancedAnnual report
「The overseas sales ratio for the first quarter of the current consolidated cumulative period was 45.8% (41.4% in the previous consolidated fiscal year).」
The overseas sales ratio rose from 41.4% in the previous consolidated fiscal year to 45.8%, numerically demonstrating the expansion of the global business foundation. - FY2022-Q2AdvancedAnnual report
「Approval for the development of Z-206 (ASACOL) in China had been obtained in April 2020, and the Chinese subsidiary of the Menarini Group, the licensee, began sales in July 2021.」
Z-206 (ASACOL) reached the sales-launch stage in China, advancing the global operations into the sales phase. - FY2022-Q1AdvancedAnnual report
「The Clostridioides difficile infection treatment DIFICLIR, for which we succeeded to the manufacturing and marketing rights in Europe, the Middle East and other regions from Astellas Pharma Europe Ltd. in November last year, has completed the succession procedures in major European countries and is already making a significant contribution to sales.」
The succession procedures for DIFICLIR in major European countries were completed, and its contribution to sales began, marking concrete progress in the global business foundation. - FY2021-Q3AdvancedAnnual report
「In addition, in November 2020, the Group's wholly owned subsidiary Tillotts Pharma AG succeeded to the manufacturing and marketing rights from Astellas Pharma Europe Ltd. for DIFICLIR tablets, a treatment for Clostridioides difficile infection, in Europe, the Middle East, Africa and the Commonwealth of Independent States.」
Tillotts Pharma AG succeeded to new manufacturing and marketing rights in Europe and other regions, adding new products and regions to the existing Europe-centered global operations. - FY2020AdvancedAnnual report
「For Acofide, a functional dyspepsia treatment developed by the Company, we entered into agreements in October 2019 with Meiji Seika Pharma Co., Ltd. covering the grant of exclusive development and sales rights in Thailand and Indonesia, and in January 2020 with Spain's FAES FARMA,S.A. covering the grant of exclusive development and sales rights in Latin America, including Brazil and Mexico and 13 countries in Central and South America.」
The Group entered into agreements granting exclusive development and sales rights for Acofide in Thailand, Indonesia and 13 Latin American countries, expanding the regions and partnership arrangements for its global operations. - FY2020-Q3AdvancedAnnual report
「Agreement concerning the exclusive development and sale of the functional dyspepsia treatment Acofide in Thailand and Indonesia / distribution and marketing agreement for the ASACOL product family in China」
The Group entered into exclusive development and sale agreements for Acofide in Thailand and Indonesia and distribution and marketing agreements for the ASACOL product family in China, expanding the specific regions and means of its global operations. - FY2019ReframedAnnual report
「In research and development, we will steadily advance the development of new drugs in Japan and overseas under a new global development structure established through collaboration with Tillotts Pharma AG.」
A new global development structure through collaboration with Tillotts Pharma AG is explicitly identified as a means of strengthening the global foundation. - FY2018ReframedAnnual report
「We are also pursuing global expansion through M&A and alliances aimed at contributing to revenue and profit and generating synergies.」
M&A and alliances are explicitly identified as means of strengthening the global foundation. - FY2017RestatedAnnual report
「In our global operations, we will work to expand our business in the rapidly growing Asian region.」
The direction of strengthening the global foundation through expansion of the Asian business continues. - FY2017-Q2AdvancedAnnual report
「Date of business combination: 20 September 2016 (the deemed acquisition date was 30 June 2016). The voting rights ratio of the additionally acquired shares was 28.89%. The purpose of this additional acquisition was to enable rapid and efficient business operations by the Group in the Asian region.」
The Group additionally acquired shares in its Vietnamese subsidiary, specifically expanding its operating foundation in Asia. - FY2016First statedAnnual report
「In this way, while steadily strengthening our foundation as a global company」
It is described as strengthening the foundation through the acquisition of overseas rights and investment in Asia.